EFFECTS OF DEXTRAN-GRAFT-POLYACRYLAMIDE/ZnO NANOPARTICLES ON PROSTATE CANCER CELL LINES IN VITRO
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18452Keywords:
apoptosis, nanoparticles, prostate cancer, zinc oxideAbstract
Background: The combination of zinc oxide (ZnO) nanoparticles (NPs) with carriers enhances the anticancer effect of nanocomposites. Aim: To explore the mechanisms of cytotoxic action of dextran-graft-polyacrylamide (D-g-PAA/ZnO) NPs against prostate cancers cell lines in vitro. Materials and Methods: Dextran-polyacrylamide was used as a matrix for the synthesis of ZnO NPs. Prostate cancer cells LNCaP, DU-145 and PC-3 were treated with D-g-PAA/ZnO NPs. The expression of Bax, Bcl-2, p53 and Ki-67 was studied using immunocytochemical analysis. Cytomorphological changes in cells were detected after their incubation with nanocomposites for 24 h. Results: The treatment with D-g-PAA/ZnO NPs caused the increase in the Bax and p53 and the decrease in Ki-67 and Bcl-2 expression. Morphological changes associated with apoptosis were registered: decrease in cell size, appearance of cytoplasmic vacuolation, condensation of chromatin, blebbing. Conclusions: Treatment with D-g-PAA/ZnO nanocomposite led to the initiation of apoptotic cell death in prostate cancer cells in vitro.
References
Rahim MA, Jan N, Khan S, et al. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers (Basel) 2021; 13: 670. https://doi.org/10.3390/cancers13040670
Xu JJ, Zhang WC, Guo YW, et al. Metal nanoparticles as a promising technology in targeted cancer treatment. Drug Deliv 2022; 29: 664–78. https://doi.org/10.1080/10717544.2022.2039804
Li S, Zhang H, Chen K, et al. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges. Drug Deliv 2022; 29: 1142–9. https://doi.org/10.1080/10717544.2022.2058646
Anjum S, Hashim M, Malik SA, et al. Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers (Basel) 2021; 13: 4570. https://doi.org/10.3390/cancers13184570
Wiesmann N, Tremel W, Brieger J. Zinc oxide nanoparticles for therapeutic purposes in cancer medicine. J Mater Chem B 2020; 8: 4973–89. https://doi.org/10.1039/d0tb00739k
Islam F, Shohag S, Uddin MJ, et al. Exploring the journey of zinc oxide nanoparticles (ZnO-NPs) toward biomedical applications. Materials (Basel) 2022; 15: 2160. https://doi.org/10.3390/ma15062160
Skrajnowska D, Bobrowska-Korczak B. Role of zinc in immune system and anti-cancer defense mechanisms. Nutrients 2019; 11: 2273. https://doi.org/10.3390/nu11102273
Singh TA, Das J, Sil PC. Zinc oxide nanoparticles: A comprehensive review on its synthesis, anticancer and drug delivery applications as well as health risks. Adv Colloid Interface Sci 2020; 286: 102317. https://doi.org/10.1016/j.cis.2020.102317
Li D, Stovall DB, Wang W, et al. Advances of zinc signaling studies in prostate cancer. Int J Mol Sci 2020; 21: 667. https://doi.org/10.3390/ijms21020667
Prasad RR, Raina K, Mishra N, et al. Stage-specific differential expression of zinc transporter SLC30A and SLC39A family proteins during prostate tumorigenesis. Mol Carcinog 2022; 61: 454–71. https://doi.org/10.1002/mc.23382
Hu C, Du W. Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells. Aging (Albany, NY) 2020; 12: 25767–77. https://doi.org/10.18632/aging.104187
Wang Y, Zhang Y, Guo Y, et al. Synthesis of Zinc oxide nanoparticles from Marsdenia tenacissima inhibits the cell proliferation and induces apoptosis in laryngeal cancer cells (Hep-2). J Photochem Photobiol B 2019; 201: 111624. https://doi.org/10.1016/j.jphotobiol.2019.111624
Ruenraroengsak P, Kiryushko D, Theodorou IG, et al. Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells. Nanoscale 2019; 11: 12858–70. https://doi.org/10.1039/c9nr01277j
Liu J, Ma X, Jin S, et al. Zinc oxide nanoparticles as adjuvant to facilitate doxorubicin intracellular accumulation and visualize pH-responsive release for overcoming drug resistance. Mol Pharm 2016; 13: 1723–30. https://doi.org/10.1021/acs.molpharmaceut.6b00311
Wang J, Lee JS, Kim D, et al. Exploration of zinc oxide nanoparticles as a multitarget and multifunctional anticancer nanomedicine. ACS Appl Mater Interfaces 2017; 9: 39971–84. https://doi.org/10.1021/acsami.7b11219
Chernykh M, Zavalny D, Sokolova V, et al. New water-soluble thermosensitive star-like copolymer as a promising carrier of the chemotherapeutic drug doxorubicin. Materials (Basel) 2021; 14: 3517. https://doi.org/10.3390/ma14133517
Viswanatha R, Sapra S, Satpati B, et al. Understanding the quantum size effects in ZnO nanocrystals. J Mat Chem 2004; 14: 661–8. https://doi.org/10.1039/B310404D
Vega-Avila E, Pugsley MK. An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc West Pharmacol Soc 2011; 54: 10-4.
Squier MK, Cohen JJ. Standard quantitative assays for apoptosis. Mol Biotech 2001; 19: 305–12. https://doi.org/10.1385/MB:19:3:305
McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. Eur J Cancer 1991; 27: 711–5. https://doi.org/10.1016/0277-5379(91)90171-9
Zadvornyi TV, Lukianova NY, Borikun TV, et al. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro. Exp Oncol 2018; 40: 184–9. https://doi.org/10.31768/2312-8852.2018.40(3):184-189
Yang R, Wu R, Mei J, et al. Zinc oxide nanoparticles promotes liver cancer cell apoptosis through inducing autophagy and promoting p53. Eur Rev Med Pharmacol Sci 2021; 25: 1557–63. https://doi.org/10.26355/eurrev_202102_24864
Khorsandi L, Farasat M. Zinc oxide nanoparticles enhance expression of maspin in human breast cancer cells. Environ Sci Pollut Res Int 2020; 27: 38300–10. https://doi.org/10.1007/s11356-020-09986-5
Pouresmaeil V, Haghighi S, Raeisalsadati AS, et al. The anti-breast cancer effects of green-synthesized zinc oxide nanoparticles using carob extracts. Anticancer Agents Med Chem 2021; 21: 316–26. https://doi.org/10.2174/1871520620666200721132522
Duan X, Liao Y, Liu T, et al. Zinc oxide nanoparticles synthesized from Cardiospermum halicacabum and its anticancer activity in human melanoma cells (A375) through the modulation of apoptosis pathway. J Photochem Photobiol B. 2020; 202: 111718. https://doi.org/10.1016/j.jphotobiol.2019.1117185
Berehu HM, S A, Khan MI, et al. Cytotoxic potential of biogenic zinc oxide nanoparticles synthesized from Swertia chirayita leaf extract on colorectal cancer cells. Front Bioeng Biotechnol 2021; 9: 788527. https://doi.org/10.3389/fbioe.2021.788527
Scherzad A, Meyer T, Kleinsasser N, et al. Molecular mechanisms of zinc oxide nanoparticle-induced genotoxicity short. Materials (Basel) 2017; 10: 1427. https://doi.org/10.3390/ma10121427
Hackenberg S, Scherzed A, Technau A, et al. Cytotoxic, genotoxic and proinflammatory effects of zinc oxide nanoparticles in human nasal mucosa cells in vitro. Toxicol in vitro 2011; 25: 657–63. https://doi.org/10.1016/j.tiv.2011.01.003
Valdiglesias V, Costa C, Kilic G, et al. Neuronal cytotoxicity and genotoxicity induced by zinc oxide nanoparticles. Environ Int 2013; 55: 92–100. https://doi.org/10.1016/j.envint.2013.02.013
Kwon JY, Lee SY, Koedrith P, et al. Lack of genotoxic potential of ZnO nanoparticles in in vitro and in vivo tests. Mutat Res Genet Toxicol Environ Mutagen 2014; 761: 1–9. https://doi.org/10.1016/j.mrgentox.2014.01.005
Mundekkad D, Cho W. Nanoparticles in clinical translation for cancer therapy. Int J Mol Sci 2022; 23: 1685. https://doi.org/10.3390/ijms23031685
Bisht G, Rayamajhi S. ZnO nanoparticles: a promising anticancer agent. Nanobiomedicine (Rij) 2016; 3: 9. https://doi.org/10.5772/63437
Sauer AK, Vela H, Vela G, et al. Zinc deficiency in men over 50 and its implications in prostate disorders. Front Oncol 2020; 10: 1293. https://doi.org/10.3389/fonc.2020.01293
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.